The LA strain has been shown to be useful in determining the effects of drugs on LA function in patients with systemic hypertension and HF [29]; nevertheless, the improvement of atrial transport function that can be obtained through the administration of angiotensin receptor (AR) blockers/angiotensin-converting enzyme inhibitors/AR-neprilysin inhibitors, beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose co-transporter-2 inhibitors in the HF setting cannot be translated entirely on atrial functional mitral regurgitation scenario [30]. The gene discussed is ACE; the disease is Hypertension.